Discovery of mutant IDH2 inhibitors for the treatment of cancer

被引：0
|
作者：
Travins, Jeremy M. [1 ]
Popovici-Muller, Janeta [1 ]
DeLaBarre, Byron [2 ]
Gross, Stefan [2 ]
Yang, Hua [4 ]
Wang, Fang [3 ]
Yen, Katherine E. [3 ]
Salituro, Francesco G. [1 ]
Saunders, Jeffrey O. [1 ]
Dang, Lenny [2 ]
Biller, Scott A. [1 ]
机构：
[1] Agios Pharmaceut, Dept Chem, Cambridge, MA 02139 USA
[2] Agios Pharmaceut, Dept Biochem, Cambridge, MA 02139 USA
[3] Agios Pharmaceut, Dept Biol, Cambridge, MA 02139 USA
[4] Agios Pharmaceut, Dept Drug Metab & Pharmacokinet, Cambridge, MA 02139 USA
来源：
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY | 2013年 / 246卷
关键词：
D O I：
暂无
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
200-MEDI
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome
    DiNardo, Courtney D.
    Venugopal, Sangeetha
    Lachowiez, Curtis
    Takahashi, Koichi
    Loghavi, Sanam
    Montalban-Bravo, Guillermo
    Wang, Xuemei
    Carraway, Hetty
    Sekeres, Mikkael
    Sukkur, Ameenah
    Hammond, Danielle
    Chien, Kelly
    Maiti, Abhishek
    Masarova, Lucia
    Sasaki, Koji
    Alvarado, Yesid
    Kadia, Tapan
    Short, Nicholas J.
    Daver, Naval
    Borthakur, Gautam
    Ravandi, Farhad
    Kantarjian, Hagop M.
    Patel, Bhumika
    Dezern, Amy
    Roboz, Gail
    Garcia-Manero, Guillermo
    BLOOD ADVANCES, 2023, 7 (11) : 2378 - 2387
  • [22] Enasidenib: First Mutant IDH2 Inhibitor for the Treatment of Refractory and Relapsed Acute Myeloid Leukemia
    Dogra, Raghav
    Bhatia, Rohit
    Shankar, Ravi
    Bansal, Parveen
    Rawal, Ravindra K.
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2018, 18 (14) : 1936 - 1951
  • [23] Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia
    Stein, Eytan M.
    DiNardo, Courtney D.
    Pollyea, Daniel A.
    Fathi, Amir T.
    Roboz, Gail J.
    Altman, Jessica K.
    Stone, Richard M.
    DeAngelo, Daniel J.
    Levine, Ross L.
    Flinn, Ian W.
    Kantarjian, Hagop M.
    Collins, Robert
    Patel, Manish R.
    Frankel, Arthur E.
    Stein, Anthony
    Sekeres, Mikkael A.
    Swords, Ronan T.
    Medeiros, Bruno C.
    Willekens, Christophe
    Vyas, Paresh
    Tosolini, Alessandra
    Xu, Qiang
    Knight, Robert D.
    Yen, Katharine E.
    Agresta, Sam
    de Botton, Stephane
    Tallman, Martin S.
    BLOOD, 2017, 130 (06) : 722 - 731
  • [24] Plk1 regulates mutant IDH1 enzyme activity and mutant IDH2 ubiquitination in mitosis
    Reddy, M. Saikiran
    Bhattacharjee, Debanjan
    Jain, Nishant
    CELLULAR SIGNALLING, 2022, 92
  • [25] NPMC COOPERATES WITH MUTANT IDH2 TO INDUCE ACUTE MYELOID LEUKEMIA
    Ogawara, Yoko
    Katsumoto, Takuo
    Aikawa, Yukiko
    Kagiyama, Yuki
    Kitabayashi, Issay
    EXPERIMENTAL HEMATOLOGY, 2013, 41 (08) : S55 - S55
  • [26] Discovery of Novel Dual Inhibitors Targeting Mutant IDH1 and NAMPT for the Treatment of Glioma with IDH1Mutation
    Wen, Fei
    Gui, Gang
    Wang, Xiaoyu
    Qin, Anqi
    Ma, Tianfang
    Chen, Hui
    Li, Chunzheng
    Zha, Xiaoming
    JOURNAL OF MEDICINAL CHEMISTRY, 2024, 67 (11) : 8667 - 8692
  • [27] FDA approves IDH1 and IDH2 inhibitor for brain cancer
    Mullard, Asher
    NATURE REVIEWS DRUG DISCOVERY, 2024, 23 (10) : 731 - 731
  • [28] Enasidenib, a targeted inhibitor of mutant IDH2 proteins for treatment of relapsed or refractory acute myeloid leukemia
    Stein, Eytan M.
    FUTURE ONCOLOGY, 2018, 14 (01) : 23 - 40
  • [29] Clinical Validation of Mutant IDH1 and IDH2 Detection by Multiplex Digital Droplet PCR
    Racchumi, J.
    Kluk, M.
    Al-Ghamdi, Y.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2020, 22 (11): : S24 - S24
  • [30] ANTICANCER DRUGS IDH2 drives cancer in vivo
    Lokody, Isabel
    NATURE REVIEWS DRUG DISCOVERY, 2013, 12 (11) : 826 - 827
12345